<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In severe <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo> <z:chebi fb="0" ids="29425">(SCN)</z:chebi>, long-term therapy with granulocyte colony-stimulating factor (G-CSF) has reduced mortality from <z:hpo ids='HP_0100806'>sepsis</z:hpo>, revealing an underlying predisposition to <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> and <z:hpo ids='HP_0011009'>acute</z:hpo> <z:mpath ids='MPATH_342'>myeloid leukaemia</z:mpath> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>We have reported the early pattern of evolution to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, but the long-term risk remains uncertain </plain></SENT>
<SENT sid="2" pm="."><plain>We updated a prospective study of 374 SCN patients on long-term G-CSF enrolled in the Severe <z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:hpo ids='HP_0001875'>Neutropenia</z:hpo> International Registry </plain></SENT>
<SENT sid="3" pm="."><plain>Long-term, the annual risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> attained a plateau (2.3%/year after 10 years) </plain></SENT>
<SENT sid="4" pm="."><plain>This risk now appears similar to, rather than higher than, the risk of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> in Fanconi <z:hpo ids='HP_0001903'>anaemia</z:hpo> and <z:mp ids='MP_0009563'>dyskeratosis</z:mp> congenita </plain></SENT>
</text></document>